H. Lundbeck A/S

We are a research-based company. We engage in research to find new drugs for treatment of CNS disorders, includ­ing depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease.These are serious disorders. They affect not only patients, but also their families and friends. Besides the stress of having a CNS disorder, patients are often exposed to prejudice because, in many sections of society, there is still far too little understanding of how adversely a CNS disorder affects an individual’s life.
We have taken upon ourselves the task of improving quality of life for persons with a psychiatric or neurological disorder, and we are working intensely to find and develop new and improved drugs. We believe that we can make a significant difference, and we are happy to do so in cooperation with others.

Contact Details: Ottiliavej 9 Copenhagen Valby DK-2500 Denmark Tel: 45 36 30 13 11 Fax: 45 36 30 19 40 Email: information@lundbeck.com WWW: www.lundbeck.com/

Recent Publications by H. Lundbeck A/S:
Binding of cyclic nucleotides to phosphodiesterase 10A and 11A GAF domains does not stimulate catalytic activity. To date eleven human PDE (3',5'-cyclic nucleotide phosphodiesterase)...	5th November, 2009	Department of Molecular Neurobiology, H. Lundbeck A/S, Ottiliavej 9, 2500	Biochem J. 2009 Oct 12;423(3):401-9. DOI Direct Link
Pharmacokinetics of sertindole and its metabolite dehydrosertindole in rats and characterization of their comparative pharmacodynamics based on in vivo D2 receptor occupancy and behavioural conditioned avoidance response. The objectives of this study were to characterize the pharmacokinetics of...	29th October, 2009	H. Lundbeck A/S R&D, 9 Ottiliavej, Copenhagen-Valby, Denmark.	Biopharm Drug Dispos. 2009 May;30(4):209-20. DOI Direct Link
Recent applications of intramolecular Diels-Alder reactions to natural product synthesis. This tutorial review presents some recent examples of intramolecular...	23rd October, 2009	H. Lundbeck A/S, Ottiliavej	Chem Soc Rev. 2009 Nov;38(11):2983-92. Epub 2009 Jul 29. DOI Direct Link
Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats. Cognitive deficits are a major clinical unmet need in schizophrenia. The...	14th October, 2009	H. Lundbeck A/S, Discovery Pharmacology Research - Cognition, Ottiliavej	Behav Brain Res. 2009 Oct 12. DOI Direct Link
Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder. Retigabine is a novel compound with anticonvulsant efficacy. Preclinical...	10th October, 2009	Department of In Vivo Neurobiology, Section of Psychiatric Symptoms, H.	Behav Brain Res. 2009 Oct 6. DOI Direct Link
→View more H. Lundbeck A/S research publications.

Press Releases on H. Lundbeck A/S:
Reportlinker Adds Alzheimer's and Parkinson's Diseases - A Global Update of Market Trends & Opportunities	18th November, 2009	Reportlinker	NEW YORK, Nov. 18 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Alzheimer's and Parkinson's Diseases - A Global Update of Market
Lundbeck Honored with the Marjorie Guthrie Leadership Award for Ongoing Commitment to the Huntington's Disease Community	9th October, 2009	Lundbeck	DEERFIELD, Ill., Oct. 9 /PRNewswire/ -- The Huntington's Disease Society of America (HDSA) recognized Lundbeck last night with the Marjorie Guthrie Leadership Award for the company's
Caraco Pharmaceutical Laboratories, Ltd. Enters Into Asset Purchase Agreement with Forest Laboratories, Inc. to Settle Lexapro(R) (escitalopram oxalate) ANDA Patent Litigation	10th July, 2009	Caraco Pharmaceutical Laboratories, Ltd.	DETROIT, July 10 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD) announced that, as part of the settlement of the legal proceedings related to Lexapro(R)
Forest Laboratories and H. Lundbeck A/S Enter Into Settlement Agreement With Sun and Caraco Related to LEXAPRO(R) Patent Litigation	10th July, 2009	Forest Laboratories, Inc.	NEW YORK, July 10, 2009 /PRNewswire-FirstCall/ -- Forest Laboratories, Inc. (NYSE: FRX) and its wholly-owned subsidiary, Forest Laboratories Holdings, Ltd. (collectively, "Forest"), and H.
Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin(R) for Insomnia in Elderly Patients	11th June, 2009		SEATTLE, June 11 /PRNewswire/ -- Neurim Pharmaceuticals (http://www.neurim.com) presented today the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin

BioNews Results for H. Lundbeck A/S:
APP Pharma cleared by FDA for hypertension drug	MarketWatch:  Oct 21 2009 7:51AM Matching: h lundbeck s
Quantitative Analysis of T-wave Morphology Increases Confidence in Drug-Induced Cardiac Repolarization Abnorma	Journal of Clinical Pharmacology:  Oct 21 2009 8:55PM Matching: h lundbeck s

H. Lundbeck A/S Patents:
US Patent No.	Title
7030252	Method for the preparation of citalopram
7148238	Phenyl-piperazine derivatives as serotonin reuptake inhibitors
7166635	3-imino-2-indolones for the treatment of depression and/or anxiety
7189720	Selective NPY (Y5) antagonists
7199135	Substituted alkyl amido piperidines
→View more H. Lundbeck A/S patents.

BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 61 individuals from H. Lundbeck A/S using this service.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 33 times since April 2007, the link to the organisation's website has been followed 3 times

Search for more companies in Copenhagen

Search for more companies in Valby

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for H. Lundbeck A/S